The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC).
Vassiliki Papadimitrakopoulou
Research Funding - Bayer/Onyx; Merck
J. Jack Lee
No relevant relationships to disclose
Ignacio Ivan Wistuba
No relevant relationships to disclose
Anne S. Tsao
No relevant relationships to disclose
Frank V. Fossella
No relevant relationships to disclose
John Heymach
No relevant relationships to disclose
Neda Kalhor
No relevant relationships to disclose
Sanjay Gupta
No relevant relationships to disclose
Scott N. Gettinger
No relevant relationships to disclose
Lauren Averett Byers
No relevant relationships to disclose
Julie Izzo
No relevant relationships to disclose
Vincent A. Miller
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Lixia Diao
No relevant relationships to disclose
Jing Wang
No relevant relationships to disclose
Caimiao Wei
No relevant relationships to disclose
Kevin R. Coombes
No relevant relationships to disclose
David J. Mauro
Employment or Leadership Position - Merck
Eric H. Rubin
Employment or Leadership Position - Merck
Waun Ki Hong
No relevant relationships to disclose
Roy S. Herbst
Research Funding - Bayer/Onyx; Merck